Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.24
-2.7%
$1.20
$0.66
$5.92
$142.11M2.232.25 million shs1.49 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$9.20
$9.63
$8.06
$18.75
$122.99M1.6946,655 shs27,956 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.94
+4.3%
$2.00
$1.12
$4.20
$144.22M0.94239,242 shs152,495 shs
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
$1.29
-1.5%
$1.27
$0.85
$2.39
$33.93M0.48157,253 shs6,830 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
0.00%-20.31%+19.16%+31.95%-64.68%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%-4.76%-5.54%-24.65%-37.67%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
0.00%-5.10%-7.46%-21.19%+31.91%
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
0.00%-0.76%+4.80%0.00%-44.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.1066 of 5 stars
3.13.00.04.72.61.70.6
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.2544 of 5 stars
3.51.00.00.02.73.30.0
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.4729 of 5 stars
3.31.00.00.02.60.00.6
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
2.2192 of 5 stars
3.05.00.00.02.20.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.22
Hold$4.14234.10% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00323.91% Upside
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50235.05% Upside
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
2.00
Hold$3.17145.48% Upside

Current Analyst Ratings Breakdown

Latest LVTX, FATE, IKT, and GLSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/15/2025
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
3/31/2025
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.50
3/28/2025
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.34M10.66N/AN/A$3.74 per share0.33
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$260K554.71N/AN/A$1.78 per share1.09
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
$4.99M6.80N/AN/A$1.95 per share0.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
-$41.97M-$1.04N/AN/AN/AN/A-62.22%-29.37%8/19/2025 (Estimated)

Latest LVTX, FATE, IKT, and GLSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/14/2025Q1 2025
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
-$0.37-$0.13+$0.24-$0.13N/AN/A
5/13/2025Q1 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
3/28/2025Q4 2024
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.29
8.29
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
6.91
6.91
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
N/A
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.20 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.35 millionNot Optionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
LAVA Therapeutics stock logo
LVTX
LAVA Therapeutics
6026.31 million26.08 millionOptionable

Recent News About These Companies

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year
Lava Therapeutics announces evaluation of strategic options

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$1.24 -0.04 (-2.75%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 +0.01 (+1.21%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$9.20 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$9.19 -0.01 (-0.11%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.94 +0.08 (+4.30%)
Closing price 04:00 PM Eastern
Extended Trading
$1.94 0.00 (0.00%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

LAVA Therapeutics stock logo

LAVA Therapeutics NASDAQ:LVTX

$1.29 -0.02 (-1.53%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 +0.07 (+5.43%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.